Drug Search Results
More Filters [+]

Tomaralimab

Alternative Names: tomaralimab, opn305, opn-305
Latest Update: 2023-03-30
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: TLR2 Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Opsona
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tomaralimab

Countries in Clinic: United Kingdom

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Parkinson's Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NM-101-01-2022

P1

Not yet recruiting

Parkinson's Disease

2024-05-30

Recent News Events